Ramipril-induced liver injury: Case report and review of the literature

American Journal of Hypertension

Volumn 26, Issue 9, 2013, Pages 1070-1075

  Douros, Antonios ^a   Kauffmann, Wolfgang ^b   Bronder, Elisabeth ^a   Klimpel, Andreas ^a   Garbe, Edeltraut ^a,c,d   Kreutz, Reinhold ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Vivantes Prenzlauer Berg ^*  (Germany)

^c LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^d UNIVERSITY OF BREMEN   (Germany)

Author keywords

blood pressure; drug induced liver injury; hypertension; ramipril.

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; ENALAPRIL; FOSINOPRIL; INSULIN DETEMIR; INSULIN LISPRO; LISINOPRIL; OMEPRAZOLE; RAMIPRIL; SIMVASTATIN;

ADULT; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; AUTOIMMUNE HEPATITIS; BLOOD EXAMINATION; CASE CONTROL STUDY; CASE REPORT; CHRONIC LIVER DISEASE; DRUG FATALITY; DRUG MONITORING; DRUG RECHALLENGE; DRUG REEXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPERTRANSAMINASEMIA; JAUNDICE; LIVER BIOPSY; MALE; MEDICATION COMPLIANCE; MEDLINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TOXIC HEPATITIS; TREATMENT WITHDRAWAL; VIRUS HEPATITIS;

BLOOD PRESSURE; DRUG-INDUCED LIVER INJURY; HYPERTENSION; RAMIPRIL.;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ALANINE TRANSAMINASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG-INDUCED LIVER INJURY; HUMANS; HYPERTENSION; JAUNDICE; LIVER; MALE; RAMIPRIL;

EID: 84882441195     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt090     Document Type: Review

References (40)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
2. Sarafidis PA, Ruilope LM. Cardiorenal disease development under chronic renin-angiotensin-aldosterone system suppression. J Renin Angiotensin Aldosterone Syst 2012; 13:217-219.
3. von Lueder TG, Krum H. RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc Drugs Ther 2013; 27:171-179.
4. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
5. Izzo JL, Weir MR. Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) 2011; 13:667-675.
6. Makani H, Messerli FH, Romero J, Wever-Pinzon O, Korniyenko A, Berrios RS, Bangalore S. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol 2012; 110:383-391.
7. Vandenburg M, Parfrey P, Wright P, Lazda E. Hepatitis associated with captopril treatment. Br J Clin Pharmacol 1981; 11:105-106.
8. Schattner A, Kozak N, Friedman J. Captopril-induced jaundice: report of 2 cases and a review of 13 additional reports in the literature. Am J Med Sci 2001; 322:236-240.
9. Hagley MT, Hulisz DT, Burns CM. Hepatotoxicity associated with angiotensin-converting enzyme inhibitors. Ann Pharmacother 1993; 27:228-231.
10. Nunes AC, Amaro P, Mac AF, Cipriano A, Martins I, Rosa A, Pimenta I, Donato A, Freitas D. Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report. Eur J Gastroenterol Hepatol 2001; 13:279-282.
11. Yeung E, Wong FS, Wanless IR, Shiota K, Guindi M, Joshi S, Gardiner G. Ramipril-associated hepatotoxicity. Arch Pathol Lab Med 2003; 127:1493-1497.
12. The Uppsala Monitoring Centre. The Use of the WHO-UMC System for Standardised Case Causality Assessment. http://who-umc.org/.
13. Garbe E, Andersohn F, Bronder E, Salama A, Klimpel A, Thomae M, Schrezenmeier H, Hildebrandt M, Spath-Schwalbe E, Gruneisen A, Meyer O, Kurtal H. Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol 2012; 68:821-832.
14. Benichou C. Criteria of drug-induced liver disorders-report of an international consensus meeting. J Hepatol 1990; 11:272-276.
15. Health & Social Care Information Centre. Prescriptions Dispensed in the Community, Statistics for England-2001-2011: Report. http://www.ic.nhs.uk.
16. US National Library of Medicine. Altace Product Information. http://dailymed.nlm.nih.gov.
17. Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 2009; 58:1555-1564.
18. Ceconi C, Francolini G, Olivares A, Comini L, Bachetti T, Ferrari R. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007; 577:1-6.
19. Kaminski DL. Arachidonic acid metabolites in hepatobiliary physiology and disease. Gastroenterology 1989; 97:781-792.
20. Shionoiri H, Nomura S, Oda H, Kimura K, Takasaki I, Takagi N, Gotoh E. Hepatitis associated with captopril and enalapril but not with delapril in a patient with congestive heart failure receiving chronic hemodialysis. Curr Ther Res Clin Exp 1987; 42:1171-1176.
21. Rosellini SR, Costa PL, Gaudio M, Saragoni A, Miglio F. Hepatic injury related to enalapril. Gastroenterology 1989; 97:810.
22. Todd P, Levison D, Farthing MJ. Enalapril-related cholestatic jaundice. J R Soc Med 1990; 83:271-272.
23. Larrey D, Babany G, Bernuau J, Andrieux J, Degott C, Pessayre D, Benhamou JP. Fulminant hepatitis after lisinopril administration. Gastroenterology 1990; 99:1832-1833.
24. Kitai E, Sandiuk A, Zalewski S. Enalapril-induced immunologic impairment of hepatic function. J Fam Pract 1991;33:301-302.
25. Hagley MT, Benak RL, Hulisz DT. Suspected cross-reactivity of enalapril-and captopril-induced hepatotoxicity. Ann Pharmacother 1992; 26:780-781.
26. Valle R, Carrascosa M, Cillero L, Perez-Castrillon JL. Enalapril-induced hepatotoxicity. Ann Pharmacother 1993; 27:1405.
27. Hilburn RB, Bookstaver D, Whitlock WL. Comment: angiotensionconverting enzyme inhibitor hepatotoxicity: further insights. Ann Pharmacother 1993; 27:1142-1143.
28. Harrison BD, Laidlaw ST, Reilly JT. Fatal aplastic anaemia associated with lisinopril. Lancet 1995; 346:247-248.
29. Droste HT, de Vries RA. Chronic hepatitis caused by lisinopril. Neth J Med 1995; 46:95-98.
30. Jeserich M, Ihling C, Allgaier HP, Berg PA, Heilmann C. Acute liver failure due to enalapril. Herz 2000; 25:689-693.
31. Gonzalez de la Puente MA, Calderon E, Espinosa R, Rincon M, Varela JM. Fatal hepatotoxicity associated with enalapril. Ann Pharmacother 2001; 35:1492.
32. Romero-Gomez M, Miralles EJ, Garcia DE, Robles A, Suarez E, Castro M. Hepatotoxicity induced by fosinopril. J Hepatol 2001; 35:309-310.
33. Hartleb M, Biernat L, Kochel A. Drug-induced liver damage-a threeyear study of patients from one gastroenterological department. Med Sci Monit 2002; 8:CR292-CR296.
34. Schoondyke JW, Mohan R, Kelly JL, Ponder MA, Iskandar S, Douglas JE. Fosinopril-induced hepatotoxicity in a complex medical patient. Tenn Med 2002; 95:155-156.
35. Macias FM, Campos FR, Salguero TP, Soria PT, Carrasco FG, Martin JM. Ductopenic hepatitis related to enalapril. J Hepatol 2003; 39:1091-1092.
36. Bas V, Erkan T, Caliskan S, Sever L, Kasapcopur O, Ozbay G, ArIsoy N. Toxic hepatitis due to enalapril in childhood. Pediatr Int 2003; 45:755-757.
37. Maimon N, Ferguson ND, Marras TK. Angiotensin converting enzyme inhibitor toxicity causing interstitial pneumonitis and cholestatic hepatitis. Eur J Intern Med 2006; 17:73.
38. Chou JW, Yu CJ, Chuang PH, Lai HC, Hsu CH, Cheng KS, Peng CY, Chiang IP. Successful treatment of fosinopril-induced severe cholestatic jaundice with plasma exchange. Ann Pharmacother 2008; 42:1887-1892.
39. da Silva GH, Alves AV, Duques P, Seva-Pereira T, Soares EC, Escanhoela CA. Acute hepatotoxicity caused by enalapril: a case report. J Gastrointestin Liver Dis 2010; 19:187-190.
40. Zalawadiya SK, Sethi S, Loe S, Kumar S, Tchokonte R, Shi D, Adam AK, May EJ. Unique case of presumed lisinopril-induced hepatotoxicity. Am J Health Syst Pharm 2010; 67:1354-1356.